Results 91 to 100 of about 871,767 (407)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance

Vascular Health and Risk Management, 2017
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic ...
Nazanin Aghel, D. Delgado, J. Lipton
semanticscholar   +1 more source

The ErbB2 receptor in gastric cancer. the quick-change artist [PDF]

, 2015
The ErbB family of receptors is providing the oncogenic signals necessary to cells to become transformed. In gastric cancer (GC) the ErbB2 (HER2) expression is associated with a poor prognosis, but addition of ErbB-targeted therapeutics to chemotherapy ...
Alimandi, Maurizio, D'Aloia, MARIA MICHELA, Malaguti, Paola   +2 more
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

“Liquid elbows” due to afatinib administration

Respiratory Medicine Case Reports, 2017
Non-small cell lung cancer adenocarcinoma in the past decade has targeted therapies as the cornerstone for therapy. In specific patients with epidermal growth factor receptor mutation have three different therapy approaches with the tyrosine kinase ...
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Konstantinos Porpodis, Anastasios Kallianos, Aggeliki Rapti, Georgia Trakada, Lemonia Velentza, Haidong Huang, Theodora Tsiouda, Wolfgang Hohenforst-Schmidt   +10 more
doaj   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Онкогематология, 2015
During therapy with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia, a number of patients demonstrate non-hematological toxicity of various degrees.
O. Y. Vinogradova
doaj   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

WNT signalling in prostate cancer [PDF]

, 2017
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-
A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine   +166 more
core   +2 more sources

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source